{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:51:03Z","timestamp":1788609063879,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jhep.2010.12.032","type":"journal-article","created":{"date-parts":[[2011,1,15]],"date-time":"2011-01-15T09:17:08Z","timestamp":1295083028000},"page":"636-646","source":"Crossref","is-referenced-by-count":170,"title":["Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients"],"prefix":"10.1016","volume":"55","author":[{"given":"Kalliopi","family":"Zachou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Papadamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini I.","family":"Rigopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2010.12.032_b0220","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2174\/092986708785747508","article-title":"Enzymes as target antigens of liver specific autoimmunity: the case of cytochromes P450s","volume":"15","author":"Bogdanos","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jhep.2010.12.032_b0225","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis","volume":"354","author":"Krawitt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2010.12.032_b0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-1-2","article-title":"Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease","volume":"1","author":"Zachou","year":"2004","journal-title":"J Autoimm Dis"},{"key":"10.1016\/j.jhep.2010.12.032_b0235","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.12.032_b0240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2010.12.032_b0245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"158","author":"Cook","year":"1971","journal-title":"Q J Med"},{"key":"10.1016\/j.jhep.2010.12.032_b0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2010.12.032_b0010","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2010.12.032_b0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/egh.09.15","article-title":"Current and future treatments of autoimmune hepatitis","volume":"3","author":"Czaja","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1478-3231.2005.01141.x","article-title":"Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy","volume":"25","author":"Seela","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2010.12.032_b0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0016-5085(87)90862-6","article-title":"Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis","volume":"92","author":"Czaja","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.12.032_b0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1478-3231.2007.01444.x","article-title":"Consequences of treatment withdrawal in type 1 autoimmune hepatitis","volume":"27","author":"Montano-Loza","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2010.12.032_b0035","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJM199510123331502","article-title":"Azathioprine for long-term maintenance of remission in autoimmune hepatitis","volume":"333","author":"Johnson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2010.12.032_b0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14740338.7.3.319","article-title":"Safety issues in the management of autoimmune hepatitis","volume":"7","author":"Czaja","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jhep.2010.12.032_b0045","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-008-0478-6","article-title":"Clinical pharmacology and pharmacogenetics of thiopurines","volume":"64","author":"Sahasranaman","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2010.12.032_b0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1478-3231.2006.01392.x","article-title":"Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases","volume":"27","author":"Tamori","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2010.12.032_b0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00281-009-0170-7","article-title":"Autoimmune hepatitis","volume":"31","author":"Vergani","year":"2009","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhep.2010.12.032_b0060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1478-3231.2005.01123.x","article-title":"Use of mycophanolate in the treatment of autoimmune hepatitis","volume":"25","author":"Oo","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2010.12.032_b0065","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","article-title":"Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis","volume":"21","author":"Sherman","year":"1994","journal-title":"J \u0397epatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0070","first-page":"771","article-title":"Tacrolimus: a potential new treatment for autoimmune chronic hepatitis: results of an open-label preliminary trial","volume":"90","author":"Van Thiel","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.12.032_b0075","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","article-title":"Short-term cyclosporine induces a remission of autoimmune hepatitis in children","volume":"30","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0080","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jhep.2010.12.032_b0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.autrev.2006.11.001","article-title":"Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?","volume":"6","author":"Iaccarino","year":"2007","journal-title":"Autoimmunity Rev"},{"key":"10.1016\/j.jhep.2010.12.032_b0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","article-title":"Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine","volume":"33","author":"Richardson","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0095","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1155\/2004\/504591","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy","volume":"18","author":"Devlin","year":"2004","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.12.032_b0100","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","article-title":"Transplant immunosupressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus","volume":"25","author":"Chatur","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2010.12.032_b0105","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","article-title":"Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease","volume":"39","author":"Czaja","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2010.12.032_b0110","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cgh.2007.02.030","article-title":"Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy","volume":"5","author":"Inductivo-Yu","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0115","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.12.032_b0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2009.02.024","article-title":"Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up","volume":"51","author":"Aw","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0125","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s10620-008-0632-0","article-title":"Mycophenolate Mofetil for autoimmune hepatitis: a single practice experience","volume":"54","author":"Wolf","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2010.12.032_b0130","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0135","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.12.032_b0145","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(00)00095-7","article-title":"Duration of immunosuppressive therapy in autoimmune hepatitis","volume":"34","author":"Kanzler","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.12.032_b0155","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1478-3231.2008.01851.x","article-title":"Occult hepatitis B virus infection in patients with autoimmune liver diseases","volume":"29","author":"Georgiadou","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2010.12.032_b0160","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1128\/CDLI.12.8.941-948.2005","article-title":"Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases","volume":"12","author":"Germenis","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jhep.2010.12.032_b0165","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jhep.2006.01.025","article-title":"Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis","volume":"44","author":"Zografos","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0170","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: the Bologna experience","volume":"50","author":"Muratori","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials","volume":"53","author":"Lamers","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","article-title":"Rapidity of treatment response and outcome in type 1 autoimmune hepatitis","volume":"51","author":"Czaja","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0185","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jhep.2005.06.006","article-title":"Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis","volume":"43","author":"Miyake","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.12.032_b0190","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2008.01904.x","article-title":"Features and consequences of untreated autoimmune hepatitis","volume":"29","author":"Czaja","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2010.12.032_b0195","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.12.032_b0200","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/lt.20453","article-title":"Mycophenolate mofetil combination therapy improves longterm outcomes after liver transplantation in patients with and without hepatitis C","volume":"11","author":"Wiesner","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.12.032_b0205","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection","volume":"345","author":"European Mycophenolate Mofetil Cooperative Study Group","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2010.12.032_b0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.12.032_b0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14656566.7.2.145","article-title":"Cost-effectiveness of pharmacotherapy for autoimmune hepatitis","volume":"7","author":"Heneghan","year":"2006","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827811000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827811000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T17:31:52Z","timestamp":1592242312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827811000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0168827811000262"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2010.12.032","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}